CHARLESTON, S.C. – Afaxys, LLC, a socially conscious healthcare company focused on serving public health professionals and their patients, today announced the appointment of Christian Bloomgren to Chief Commercial Officer (CCO). In this role, Christian will be responsible for leading the identification, development, and execution of marketing and sales strategies across Afaxys Pharma and Afaxys Group Services (AGS) to deliver on the Company’s commercial objectives and growth initiatives.
“The U.S. reproductive health landscape has changed and access to necessary healthcare and products continues to be a real challenge. Christian is joining Afaxys to help us continue to ensure affordable access for those that need it most,” said Ronda Dean, President, CEO & Co-Founder of Afaxys. “We look forward to his proven leadership, strategic vision, and expertise, helping us advance our mission and optimize the adoption and distribution of Afaxys’ products in public health. On behalf of the Board of Directors and my Executive Team, I would like to congratulate and officially welcome Christian to Afaxys.”
“Afaxys has a powerful mission and has already made a significant impact to healthcare professionals and their patients through its focus on sexual and reproductive healthcare in the public health sector. The company is entering an exciting time of strategic growth, and I’m proud to join this talented team to leverage the collective strengths of Afaxys Pharma and Afaxys Group Services to continue building upon our legacy of leadership in public health,” said Bloomgren.
Christian Bloomgren has over 20 years of experience building and leading companies across the pharmaceutical, women’s health, diagnostic, biotech, and medical device markets. His previous roles include Chief Commercial Officer at Infinate Health, President & Chief Commercial Officer at Dominion Aesthetic Technologies, and Senior Vice President, Sales at TherapeuticsMD.
Afaxys uniquely partners with public health and private industry to ensure healthcare providers have stable pricing and reliable access to the products and services they need to care for their patients.
The Afaxys enterprise comprises a family of companies that operate under two wholly owned subsidiaries: Afaxys Pharma, LLC and Afaxys Group Services, LLC (AGS). Afaxys Pharma provides a broad portfolio of branded and generic contraceptives to the public healthcare market. AGS is a strategic sourcing operation that negotiates favorable pricing across a broad base of products and services through its Group Purchasing Organization and emapp. For more information visit www.afaxys.com.
The statements in this press release that are not historical facts constitute “forward-looking statements” as defined by Federal Securities laws. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from future results expressed or implied by such forward-looking statements. Potential risks and uncertainties include, but are not limited to, risks related to the inability to implement strategic initiatives, and the dependence on key personnel. Forward-looking statements speak only as of the date they are made. Afaxys, Inc. will not update forward-looking statements to reflect factual assumptions, circumstances or events that have changed after a forward-looking statement was made.